NCT06934408

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Injections of HRS-5817 Injection in Healthy Adult Volunteers With or Without Obesity

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 92 (estimated)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5817 when administered subcutaneously (SC) as single and multiple doses in adults who are affected by obesity.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	HRS-5817 Injection	HRS-5817 injection administered subcutaneously (SC).
DRUG	HRS-5817 Injection Placebo	HRS-5817 injection placebo administered subcutaneously (SC).

Timeline

• Start date: 2025-05-08
• Primary completion: 2027-04-01
• Completion: 2027-04-01
• First posted: 2025-04-18
• Last updated: 2025-11-17

Locations

1 site across 1 country: China